Retatrutide Pills: Do They Exist, and What Can You Take Instead?

By The RX Index Editorial Team · Last verified October 2026

No retatrutide pills are FDA-approved. Retatrutide is being studied as Eli Lilly's once-weekly injection, and FDA says it cannot be compounded under federal law. Pills, capsules, drops, or strips sold under that name are not approved substitutes. For eligible adults who prefer a pill, Foundayo and Wegovy tablets are different, FDA-approved GLP-1 medicines. (FDA; Foundayo; Wegovy.)

The longer answer has a catch most people miss: Lilly does sell a weight-loss pill, and it's not retatrutide. Below, you'll see exactly what's behind each "reta pill" name, what the two approved GLP-1 pills cost by the month, and the questions that help decide which fits you.

RX Index Decision Verdict: Don't buy anything sold as retatrutide pills; discuss approved pill options such as Foundayo and the Wegovy pill with a clinician. Best for: Anyone who saw a "reta pill" ad, hates needles, or wants to explore an approved treatment now. Not ideal for: People set on retatrutide itself. Lilly's current program is an injection, and there's no FDA approval date. The factor that matters most: The medicine's real name and form — not whether it skips the needle.

One honest limit before we start: we haven't tested any product sold online as retatrutide. A label or lab certificate alone can't tell you whether that product is safe and works in people. That's the whole problem. What we can do is show you what the official sources say about each name, so you can check any ad yourself.

Retatrutide pills vs. what's real: what's behind each name

No product sold as a retatrutide pill, capsule, drop, or strip is FDA-approved. Lilly's current retatrutide program uses a weekly injection. Foundayo and the Wegovy pill are different, FDA-approved GLP-1 medicines for weight loss. Here's the map, checked October 15, 2026. (FDA; Lilly; pill labels, Wegovy.)

What's behind the pill name? U.S. approval and form check, October 15, 2026

Retatrutide products and research — not FDA-approved

Sources: FDA's retatrutide and research-product warnings, Lilly's retatrutide overview, and Lilly Medical's expanded-access rules. The last column concerns treatment, not sales for genuine laboratory research.

Different medicines — FDA-approved oral GLP-1 options for weight loss

Notice the Foundayo row. Lilly makes both retatrutide and Foundayo. That's where the mix-up can start. Someone says "Lilly's new weight-loss pill," and it gets heard as "the retatrutide pill." They're two separate drugs with different labels and different results.

Already took something sold as retatrutide? Skip to what to do now.

Why isn't there a retatrutide pill?

Retatrutide is a peptide, a small chain of protein building blocks. Digestive breakdown and poor absorption make peptides hard to turn into pills. Lilly's current program uses shots under the skin; we found no announced retatrutide pill in the sources checked. (Retatrutide research; oral-peptide absorption research; Lilly.

Think of swallowing an unprotected peptide like mailing a letter through a paper shredder: it can break down before it arrives. Getting the medicine into the blood takes more than putting it in a capsule. The two approved GLP-1 pills use different approaches:

• Add a helper and strict rules. The Wegovy pill pairs semaglutide with SNAC, an ingredient that helps it get absorbed in the stomach. Its label calls for a morning dose on an empty stomach, with no more than 4 ounces of water, followed by at least 30 minutes before food, other drinks, or other oral medicines. The tablet is swallowed whole (Wegovy label).
• Build a different kind of molecule. Foundayo isn't a peptide at all. It's a small-molecule medicine, and its label allows it to be taken with or without food. Its tablet is also swallowed whole (Foundayo label).

Neither approach makes those pills oral retatrutide. You may also see retatrutide called "GLP-3." Lilly says that nickname is scientifically inaccurate. Retatrutide is a "triple agonist," which means it acts on three hormone receptors at once: GIP, GLP-1, and glucagon (Lilly). Neither approved GLP-1 pill acts on all three receptors (Foundayo; Wegovy).

Does the evidence match the pill, drop, or strip?

A real study can still be the wrong evidence for a product. The retatrutide studies checked here used injections, so their results don't establish how a pill or strip works. Before you trust a claim, check that the study used the same medicine in the same form.

Say an ad for a "retatrutide strip" links to a big trial. You click it. The trial is real: Lilly reported 28.3% average weight loss with retatrutide 12 mg over 80 weeks in adults with obesity, or overweight with a related health problem, without diabetes. That estimate assumes people remained on study treatment without starting prohibited weight treatments (Lilly, TRIUMPH-1). But the people in it got weekly shots. The trial never tested the strip. That's a mismatch, not proof.

Use this table on any ad or seller page:

Sources for the drug, compounding, and access checks: Lilly's trial report, FDA, Foundayo's label, and Lilly Medical. A certificate tests what it describes; it does not replace clinical evidence for the finished product.

Not sure which path fits you?

Wanting a pill narrows things down, but it doesn't settle the choice. The right path depends on your state, your insurance and its formulary (the list of drugs your plan covers), whether you'd consider a shot, your budget, and your health history. Use The RX Index's Find My GLP-1 Path tool to see suggested paths and providers before you choose. It's free, takes about 2 minutes, and needs no signup. It does not check your plan's actual coverage or decide whether a medicine is safe for you.

See which GLP-1 path fits you

Is it safe to take a product sold as retatrutide?

A seller's label cannot establish that a product is safe. FDA warns that retatrutide products sold to consumers under research labels are of unknown quality and may be harmful. Lilly's trials and its narrow physician-requested program are different from buying a product online. (FDA; Lilly Medical.)

Here's what the official record shows, as of October 15, 2026:

• The FDA has warned telehealth companies for marketing retatrutide, ingredient suppliers for selling it to compounders, and outsourcing facilities for repackaging it (FDA).
• It has also warned companies marketing retatrutide for human use despite labels such as "for research" or "not for human consumption" (example warning letter).
• Lilly says illicit products may contain unknown ingredients, contaminants, too much or too little drug, or the wrong drug entirely (Lilly).

A pill or drop adds one more unknown on top of all that. Even if a product contained retatrutide, its label would not establish how much reaches your blood when swallowed or held under the tongue. We did not verify human absorption data for these marketed oral products. A familiar drug name doesn't fill that gap.

If you already bought or took a product sold as retatrutide

Keep the package, and tell a doctor or pharmacist exactly what you took and when. If you think you've been poisoned, call Poison Help at 1-800-222-1222 now. Don't wait for symptoms. (Poison Help.)

• Call 911 if someone collapses, has a seizure, has trouble breathing, or cannot be awakened. For other suspected poisoning, call Poison Help right away; do not wait for symptoms. Tell the poison expert about symptoms such as severe belly pain, repeated vomiting, or a racing heart (Poison Control; Poison Help).
• Bring the label, the seller's name, and when you took it. That helps the clinician figure out what they're dealing with.
• You can report a problem to the FDA through MedWatch.

People with type 1 diabetes, people who are pregnant or planning to be, anyone under 18, and anyone with a history of an eating disorder should talk with their own care team before trying any weight-loss medicine.

When could real retatrutide be available?

Lilly plans to submit retatrutide to the FDA in the first quarter of 2027. There's no approval date. The program Lilly describes is a weekly injection, not a pill. (Lilly's September 29 update.)

A filing is not approval, and a review target is not a launch date. FDA describes goals of 10 months for standard review and six months for priority review; those goals do not establish the earliest possible retatrutide decision. We cannot turn Lilly's filing plan into a promised approval month (FDA).

The two medical access paths documented by the sources checked are:

1. A Lilly clinical trial. You can search for one on ClinicalTrials.gov. A listing does not guarantee an open local site or that you qualify.
2. A narrow expanded-access program. Your doctor has to request it, not you. Lilly supplies the drug at no cost and does not ship it directly to patients. Visits, tests, and other care can still cost extra. The bar is high: adults 18 or older; BMI of 35 or higher despite taking and tolerating the highest available dose of a chronic weight-management medicine; at least two serious or life-threatening obesity-related complications receiving standard care; no workable retatrutide or comparable trial; and a discussion of all standard options, including weight-loss surgery. A medical reason not to use retatrutide excludes a patient. Lilly reviews each request, and geography, supply, FDA, and ethics-board requirements still matter (Lilly Medical, reviewed Aug 26, 2026). We break it down in Lilly's retatrutide early access rules.

For the full access picture, see when retatrutide will be available.

Which real pill fits you: Foundayo or the Wegovy pill?

Foundayo and the Wegovy pill are the two FDA-approved GLP-1 pills for weight loss. Both are once-daily prescription tablets for adults with obesity, or with overweight plus a weight-related health problem, alongside reduced-calorie eating and physical activity. A big everyday difference is the morning routine. (Foundayo label; Wegovy label.)

Sources: Foundayo label, Trial 1, Lilly's coverage and savings terms, Wegovy label, Study 7, NovoCare pricing, and CMS Bridge rules. Both pill figures include all randomized participants and account for stopping treatment. The Foundayo trial used an earlier formulation; its approved label identifies the equivalent marketed dose. These were separate trials, not a head-to-head study.

The pill trials reported smaller averages than the retatrutide injection result above. But the studies differed in length, patients, and analysis: the 28.3% retatrutide figure assumes staying on treatment, unlike the pill figures shown here. That does not prove which medicine would work better for you. The real choice today is whether an approved option fits, rather than counting on an unapproved drug (Lilly's trial report).

The quick way to choose:

• Can you take a pill on an empty stomach every morning and wait 30 minutes? If yes, the Wegovy pill is an option. If that routine won't work for you, Foundayo's any-time dosing matters more.
• Open to a weekly shot as well as a pill? Compare the approved injections in the best GLP-1 for weight loss.
• On Medicare Part D? Ask whether the $50 Bridge applies to your weight-management prescription. See Medicare and Foundayo and Medicare and the Wegovy pill.

For the full side-by-side, read Wegovy pill vs. Foundayo.

The $25 and $50 figures have different rules. The commercial savings offers require eligible commercial coverage, are not for government-program beneficiaries, and do not guarantee a $25 final bill. Foundayo's covered-insurance card caps savings at $100 per 30-day fill, $1,000 per calendar year, and 10 fills; Wegovy's offer caps savings at $100 per monthly fill. Foundayo's card expires December 31, 2026. See the Lilly and NovoCare terms.

The Medicare GLP-1 Bridge is separate from ordinary Part D drug coverage and runs from July 1, 2026 through December 31, 2027. Both pills are included, but an eligible plan and a prescriber's prior authorization are required. Its clinical rules are narrower than the drug labels: BMI 35+, or lower BMI thresholds with specified conditions. Prescriptions for uses covered under ordinary Part D belong with the plan instead. Start with your prescriber and CMS's rules, not a cash-pay membership.

What the two real pills actually cost

Both pills have a $149 starting-dose self-pay price, but that is not the price for every dose. Foundayo's highest doses are $299 with the offer or $349 at regular self-pay pricing; Wegovy's 9 mg and 25 mg tablets are $299. Prices below were checked October 15, 2026.

That $149 is the sticker price for the starting dose, not the whole receipt. Match the price to the dose your clinician prescribes. This is a price list, not a schedule for raising a dose.

Checked at LillyDirect, Lilly's detailed terms, NovoCare, and Ro. These are U.S. medication-only self-pay offers for eligible patients, not insurance copays. Additional taxes or fees can apply; required care is separate.

Foundayo's refill catch: The first purchase of 14.5 mg or 17.2 mg gets the $299 offer automatically. After that, the next refill purchase must be completed within 45 days of delivery or receipt of the previous prescription to keep the offer. A later purchase loses the offer and the regular price is $349. The reduced 2.5 mg and 5.5 mg prices run through December 31, 2026 (Lilly's terms).

Can you turn these prices into a year-one total? Not a reliable one. NovoCare says its Wegovy pricing will be updated after December 31, 2026, and Lilly's offers can change. Your prescribed doses and refill timing also change the bill. A year starting now crosses into 2027.

Here is the arithmetic at today's prices, not a quote for the next year:

Twelve 30-day fills cover 360 days, not a full calendar year. The example does not tell you when or whether to raise a dose. It assumes the stated prices apply to every counted fill and excludes visits, membership, taxes, and extra fees. A missing cost is not $0.

What changes your total

Where you get the prescription changes the bill. Ro's posted single-fill offers match the manufacturer offers checked here, but Ro adds a membership. With your own doctor, visit and lab costs depend on the practice and your coverage. (Ro pricing; Lilly; NovoCare.)

The last two columns reuse the hypothetical 12-fill medication totals above. They are cash-flow examples, not guaranteed annual bills or a claim that every path includes the same care.

*Arithmetic: 12 monthly Ro membership charges total $39 + (11 × $149) = $1,678. The introductory month plus a prepaid annual term costs $39 + $888 = $927, but buys 13 membership months, not 12. Adding those cash outlays to the illustrative medication totals gives the amounts shown. The prepaid row is therefore not a like-for-like 12-month service comparison. The Medicare example is 12 × $50 and includes no visit fees. Manufacturer, card, and program changes can change all future totals.

When Ro charges: Its pricing FAQ says medication is charged once you are approved for treatment; membership and medication are separate charges. Its terms put the exact timing at checkout and promise a refund if medication is never prescribed. We did not complete checkout, so this table does not say that $39 + $149 is collected together when you first enter the site (pricing FAQ; terms).

Before prepaying: Ro's terms say paid membership fees are non-refundable, apart from stated exceptions such as no medication being prescribed. Cancel at least 48 hours before renewal to avoid another membership charge; service continues through the paid billing cycle. The terms include up to 24 medical consults per year, messaging, and provider-ordered lab testing. Consults beyond 24 cost $15 each; additional lab tests are priced separately. Confirm any other required charge before paying (Ro terms).

Here's a candid point about Ro. Its insurance help covers the Ozempic, Wegovy, and Zepbound autoinjector pens, not the pills. On Ro, both pills are cash-pay only (Ro). If you already have a doctor willing to prescribe, filling at LillyDirect or NovoCare Pharmacy skips the membership. What Ro adds is online clinician visits and ongoing care in one place, with a prescription only if appropriate. Its multi-month medication offers can have different prices and prepayment terms from the single-fill prices shown here (Ro pricing).

Check your health fit before anything else

A pill isn't automatically safer than a shot. Both pills carry serious warnings, and a clinician needs to review your health history and every medicine you take.

Neither pill is for you if you or a family member has had medullary thyroid carcinoma (a rare thyroid cancer), if you have MEN 2 (an inherited gland condition), or if you've had a serious allergic reaction to the drug. Neither should be combined with another GLP-1. Common side effects are stomach issues like nausea, diarrhea, and constipation. Serious risks include pancreatitis (inflammation of the pancreas) and kidney problems from dehydration. If you take birth control pills, Foundayo's label calls for a barrier method, such as condoms, or a non-oral contraceptive for 30 days after starting and after each dose increase. Pregnancy, or plans for one, needs a talk with your clinician first. (Foundayo prescribing information, Wegovy label. More in GLP-1 hard contraindications and Foundayo drug interactions.)

Not sure you'd qualify? Both labels describe adults with obesity, or overweight plus a weight-related condition. Their weight-loss trials used a BMI of 30 or higher, or 27 or higher with a condition such as high blood pressure. BMI is a number based on height and weight, not medical clearance. A clinician makes the call (Foundayo label; Wegovy label). Take this to your appointment:

"I'd rather take a pill than a shot. Is Foundayo or the Wegovy pill right for me? Please check my health history and the medicines I take. Which one should I ask my insurance about, and what will the full cost be?"

You don't have to settle the whole decision before the appointment. Bring the question above and ask the clinician to check the medicine, the routine, and the full cost together.

Should you wait for retatrutide instead?

There is no confirmed approval date to plan around, and Lilly's current retatrutide program is an injection. Starting an approved medicine now doesn't stop you from talking with your clinician about retatrutide later. Ask your clinician whether delaying treatment makes sense for your health (Lilly).

Say you're 45, your BMI is 33, and needles make you queasy. Waiting for retatrutide means waiting for an uncertain approval decision about an injection. An approved pill could fit your life better if your clinician finds it suitable. If you'd rather hold out, discuss the risks of delaying care too. Just don't fill the gap with a product sold online as retatrutide.

For a deeper look at the trade-off, see retatrutide vs. Foundayo and retatrutide weight loss results.

What we actually verified

Last verified October 2026. We checked the FDA's current position on retatrutide, Lilly's own retatrutide pages and trial reports, both pill labels, Lilly's expanded-access rules, and current published prices on October 15, 2026. We did not buy, test, or check the contents of any product sold as retatrutide.

• FDA status and compounding: FDA's unapproved GLP-1 page (content current as of October 1, 2026) and an FDA warning letter naming retatrutide.
• Retatrutide form and timeline: Lilly's retatrutide FAQ (updated September 2026), its May 21 and September 29, 2026 trial-results releases, and the primary discovery paper's indexed abstract. The retatrutide weight-loss figure is sponsor-reported, not a result we independently reanalyzed.
• Expanded access: Lilly Medical's answer, last reviewed August 26, 2026. Its specific program guidance documents an exception to the broad FAQ's trials-only wording.
• The two pills: the FDA's Foundayo approval notice, FDA-hosted Foundayo prescribing information (April 2026), the manufacturer's Foundayo information, and Wegovy prescribing information (revised June 2026). We checked the trial tables for the figures shown.
• Prices and billing: LillyDirect, Lilly's detailed offer terms, NovoCare, and Ro's pricing and terms, all checked October 15, 2026. Prices are what each company publishes. We didn't complete a checkout.
• Medicare and urgent help: CMS's Bridge rules, Poison Help's instructions, and Poison Control's emergency guidance. We did not check any reader's coverage or eligibility.
• What we couldn't confirm: what any online retatrutide product contains, matching human evidence for marketed oral retatrutide products, your full future treatment bill, or whether Lilly will ever make a pill.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation. Here's how we evaluate treatment paths.

Retatrutide pills FAQ

Is retatrutide a shot or a pill?

It's an injection in Lilly's current development program. It isn't FDA-approved in any form, and a website selling "oral retatrutide" doesn't change that (Lilly; FDA).

Is Lilly's weight-loss pill retatrutide?

No. Lilly's pill is Foundayo, and its active ingredient is orforglipron, a different medicine. Lilly makes both, which can cause confusion (FDA's Foundayo approval).

Will there ever be a retatrutide pill?

We found no announced retatrutide pill in Lilly's sources checked for this page. Retatrutide is a peptide, and digestive breakdown and absorption are barriers to oral delivery. Foundayo is a separate drug, not a pill version of retatrutide (Lilly; oral-peptide research; Foundayo label).

When will retatrutide be available?

Lilly plans to submit it to the FDA in the first quarter of 2027. There's no approval date, and the current program studies a weekly injection. The medical access paths documented here are Lilly's trials and a narrow program your doctor has to request (Lilly's filing plan; expanded access).

Do retatrutide drops or strips work like the injection?

We did not verify matching human evidence that marketed retatrutide drops or strips work like the injection. A study of injected retatrutide can't establish how a drop or strip works, even when an ad links to a real trial. These products also aren't FDA-approved, and FDA says retatrutide cannot be compounded under federal law (FDA).

Can a compounding pharmacy make retatrutide pills?

No. The FDA says retatrutide cannot be used in compounding under federal law. A prescription doesn't change that (FDA).

What's the closest pill to retatrutide?

Neither Foundayo nor the Wegovy pill acts on all three receptors retatrutide does. They are different FDA-approved GLP-1 pills for weight loss, not oral replacements for retatrutide. Their trial results do not establish which would work better for an individual (Foundayo; Wegovy; Lilly).

How much do the real weight-loss pills cost?

Both have $149 starting-dose self-pay offers per 30-day supply, checked October 15, 2026. Wegovy's 9 mg and 25 mg tablets are $299; Foundayo's highest doses are $299 with the offer or $349 at regular pricing. Eligible commercial savings-card users may pay as little as $25, subject to limits; eligible Medicare GLP-1 Bridge patients pay $50 per monthly fill. Membership and care costs are separate, and the 12-fill examples above are not guaranteed year-one quotes (Lilly; NovoCare; CMS).

Is a pill safer than a shot?

Not automatically. The risks depend on the medicine and on you, not on whether there's a needle. Both approved pills carry serious warnings and need a clinician's review (Foundayo; Wegovy).

Still not sure which GLP-1 path fits you? Take The RX Index's free Find My GLP-1 Path quiz — about 2 minutes, no signup.

Find my GLP-1 path

Sources

Checked October 15, 2026. Dates in parentheses belong to the source or policy, not this page. Primary research abstracts support only the specific identity or absorption statements cited; trial-results releases are labeled sponsor reports.

• FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of October 1, 2026).
• FDA — Warning letter: Prime Sciences, March 31, 2026.
• Eli Lilly — What to know about retatrutide (updated September 2026; its broad trials-only wording has the expanded-access exception below).
• Eli Lilly — TRIUMPH-1 results (May 21, 2026; Lilly-issued release carried by PR Newswire).
• Eli Lilly — TRIUMPH-2 results and filing plan (September 29, 2026; sponsor report).
• Lilly Medical — Is there an expanded access program for retatrutide? (last reviewed August 26, 2026).
• FDA — Foundayo approval (April 1, 2026).
• FDA — Foundayo prescribing information (April 2026 approval label).
• Eli Lilly — Foundayo prescribing information (manufacturer-hosted version checked October 15, 2026).
• Novo Nordisk — Wegovy prescribing information (revised June 2026).
• Coskun and colleagues — LY3437943 discovery and clinical proof of concept, Cell Metabolism (2022; indexed abstract checked for retatrutide's peptide identity).
• Buckley and colleagues — Transcellular stomach absorption of a GLP-1 receptor agonist, Science Translational Medicine (2018; indexed abstract checked for oral-peptide delivery barriers; product-specific administration comes from the current label).
• LillyDirect — Foundayo self-pay pricing.
• Eli Lilly — Foundayo coverage, card, and Self-Pay Journey offer terms.
• NovoCare — Wegovy savings and self-pay pricing.
• Ro — Weight-loss pricing, medication options, and Terms of Use.
• CMS — Medicare GLP-1 Bridge and information for providers (program period July 1, 2026–December 31, 2027).
• HRSA — Poison Help: What You Can Do.
• National Capital Poison Center — Poison Control: emergency guidance.
• FDA — MedWatch reporting.
• FDA — Priority Review (review goals, not a retatrutide decision date).
• ClinicalTrials.gov — Retatrutide studies (search destination, not a claim that a particular site is enrolling).